Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3β phosphorylation and p21 down-regulation in hepatocellular carcinoma

Sorafenib (Nexavar), a multiple kinase inhibitor, is the only clinically approved drug for patients with advanced HCC. However, its therapeutic success is limited by the emergence of drug resistance. Here we found that p21 and pGSK3β(Ser9) are major players in the resistance to sorafenib. We recentl...

Descripción completa

Detalles Bibliográficos
Autores principales: Giovannini, Catia, Baglioni, Michele, Toaldo, Marco Baron, Ventrucci, Cristiano, D'Adamo, Stefania, Cipone, Mario, Chieco, Pasquale, Gramantieri, Laura, Bolondi, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2013
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858550/
https://www.ncbi.nlm.nih.gov/pubmed/24113128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858550/
https://www.ncbi.nlm.nih.gov/pubmed/24113128

Ejemplares similares